1273-PUB: A Comparison of Efficacy and Safety of Remogliflozin and Vildagliptin as Second-Line Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone over One Year in Real-World Settings in India

Background: Remogliflozin had recently got approval in India as new SGLT2i and also there was a storm of Vildagliptin generics after it loses its exclusive marketing patent. Method: This was a 48 weeks prospective observational study (N=254, age ≥ 35 years with HbA1c ≥ 7%). According to investigator decision, eligible patients were assigned either remogliflozin 100 mg BD ( N=980) or Vildagliptin 50 mg BD (N= 1420) in patients who were initially uncontrolled on metformin 1000 mg alone in single or divided doses for atlas 6 weeks. Primary outcome was change in HbA1c, FBS and PPBS, secondary outcome was proportion of patients with HbA1c0.001) than vildagliptin plus metformin (-1±0.3%;8.3±1.3% to 7.3±0.6%, p>0.001). 62% patients on remogliflozin were achieved target HbA1c level within 24 weeks where as it was 57% with vildagliptin group. Differences were found in: SBP -7.92 mmHg (p